International multi-site initiative to develop an mri-inclusive nomogram for side-specific prediction of extraprostatic extension of prostate cancer
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 1,16 MB, PDF-dokument
Background: To develop an international, multi-site nomogram for side-specific prediction of extraprostatic extension (EPE) of prostate cancer based on clinical, biopsy, and magnetic resonance imaging-(MRI) derived data. Methods: Ten institutions from the USA and Europe contributed clinical and side-specific biopsy and MRI variables of consecutive patients who underwent prostatectomy. A logistic regression model was used to develop a nomogram for predicting side-specific EPE on prostatectomy specimens. The performance of the statistical model was evaluated by bootstrap resampling and cross validation and compared with the performance of benchmark models that do not incorporate MRI findings. Results: Data from 840 patients were analyzed; pathologic EPE was found in 320/840 (31.8%). The nomogram model included patient age, prostate-specific antigen density, side-specific biopsy data (i.e., Gleason grade group, percent positive cores, tumor extent), and side-specific MRI features (i.e., presence of a PI-RADSv2 4 or 5 lesion, level of suspicion for EPE, length of capsular contact). The area under the receiver operating characteristic curve of the new, MRI-inclusive model (0.828, 95% confidence limits: 0.805, 0.852) was significantly higher than that of any of the benchmark models (p < 0.001 for all). Conclusions: In an international, multi-site study, we developed an MRI-inclusive nomogram for the side-specific prediction of EPE of prostate cancer that demonstrated significantly greater accuracy than clinical benchmark models.
| Originalsprog | Engelsk |
|---|---|
| Artikelnummer | 2627 |
| Tidsskrift | Cancers |
| Vol/bind | 13 |
| Udgave nummer | 11 |
| Antal sider | 14 |
| ISSN | 2072-6694 |
| DOI | |
| Status | Udgivet - 2021 |
Bibliografisk note
Funding Information:
Conflicts of Interest: A.G.W., F.A., A.D.J.B., L.B., F.B.F., R.C., H.C., V.C., S.C., S.D., J.E., F.M.F., K.G., M.H., A.W.L., X.J., V.L., P.C.M., V.P., P.P., J.P.R., O.R., P.C.S., J.C.V., J.W., A.S.-D.: no conflict of interest; M.W.K.: consultant for Stratify Genomics; D.B.: Bayer Vital, Bayer GmbH, Bayer Healthcare: reception of honorary membership and travel expenses due to lectures held; D.J.M.: institutional in-kind grant from Siemens Healthineers, ad-hoc consulting for Promaxo; T.P.: supported by Berlin Institute of Health (Clinician Scientist Grant, Platform Grant) and reports research agreements (no personal payments, outside of submitted work) with AGO, Aprea AB, ARCAGY-GINECO, Astellas Pharma Global Inc. (APGD), Astra Zeneca, Clovis Oncology, Inc., Dohme Corp, Holaira, Incyte Corporation, Karyopharm, Lion Biotechnologies, Inc., MedImmune, Merck Sharp, Millennium Pharmaceuticals, Inc., Morphotec Inc., NovoCure Ltd., PharmaMar S.A. and PharmaMar USA, Inc., Roche, Siemens Healthineers, and TESARO Inc; H.-P.S.: Bayer Vital, Bayer GmbH, Bayer Healthcare and Siemens Healthineers: reception of honorary membership and travel expenses due to lectures held; C.M.T.: NIH support, Medical advisor: Profound Medical and Promaxo, Clinical Trial support: Insightec; H.H.: Hricak serves on the Board of Directors of Ion Beam Applications (IBA) and receives annual compensation for her service. She also serves, without compensation, on the External Advisory Board, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; the International Advisory Board, University of Vienna; and the Scientific Committee and Board of Trustees, DKFZ (German Cancer Research Center). Her work on this manuscript was supported by the NIH/NCI P30 Cancer Center Support Grant (CCSG) (P30 CA008748) to Memorial Sloan Kettering Cancer Center. The NIH/NCI had no role in the study, the preparation of the manuscript, or the decision to submit it for publication.
Funding Information:
Funding: The work of investigators at Memorial Sloan Kettering Cancer Center was supported in part through the NIH/NCI Cancer Center Support Grant P30 CA008748, as well as through the Peter Michael Foundation and the Strawbridge Foundation.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
ID: 302452425